Search results for "Open"

showing 10 items of 3963 documents

Prediction of complexity and complications of laparoscopic liver surgery: The comparison of the Halls‐score to the IWATE‐score in 100 consecutive lap…

2020

BACKGROUND The development of laparoscopic liver surgery is slower than in other disciplines. Two different scoring systems have been proposed to estimate difficulty of laparoscopic liver resections (LLR) preoperatively. The aim of this analysis was to compare these two scores in an independent patient cohort regarding the predictability of morbidity. METHODS All LLRs performed between 01/2011 until 01/2019 were identified from our prospective institutional database. Patient characteristics as well as intra- and postoperative data were analyzed. Postoperative complications were graded according to Dindo-Clavien classification. Difficulty of LLR was classified using IWATE- and Halls-score. R…

AdultMaleLiver surgerymedicine.medical_specialtyCirrhosisOperative TimeBlood Loss SurgicalPatient characteristics030230 surgeryLiver resectionsSeverity of Illness Index03 medical and health sciencesPostoperative Complications0302 clinical medicineBlood lossPredictive Value of TestsmedicineHepatectomyHumansProspective StudiesAgedAged 80 and overHepatologybusiness.industryLiver NeoplasmsCurve analysisLength of StayMiddle Agedmedicine.diseaseConversion to Open SurgeryMagnetic Resonance ImagingSurgery030220 oncology & carcinogenesisCohortFemaleLaparoscopySurgeryTomography X-Ray ComputedbusinessHospital stayJournal of Hepato-Biliary-Pancreatic Sciences
researchProduct

Safety of Long-Term Oral Posaconazole Use in the Treatment of Refractory Invasive Fungal Infections

2005

Background Invasive fungal infections are found most frequently in immunosuppressed and critically ill hospitalized patients. Antifungal therapy is often required for long periods. Safety data from the clinical development program of the triazole antifungal agent, posaconazole, were analyzed. Methods A total of 428 patients with refractory invasive fungal infections (n = 362) or febrile neutropenia (n = 66) received posaconazole in 2 phase II/III open-label clinical trials. Also, 109 of these patients received posaconazole therapy for > or = 6 months. Incidences of treatment-emergent, treatment-related, and serious adverse events and abnormal laboratory parameters were recorded during these…

AdultMaleMicrobiology (medical)Posaconazolemedicine.medical_specialtyAntifungal AgentsAdolescentNauseaQT intervalDrug Administration ScheduleInternal medicinemedicineHumansAdverse effectMycosisAgedDose-Response Relationship Drugbusiness.industryMiddle AgedTriazolesmedicine.diseaseSurgeryClinical trialInfectious DiseasesMycosesVomitingFemalemedicine.symptombusinessFebrile neutropeniamedicine.drugClinical Infectious Diseases
researchProduct

Caspofungin for the treatment of candidaemia in patients with haematological malignancies

2010

AbstractThis study was prospectively conducted in 11 haematology divisions over a 2-year period to evaluate the efficacy of caspofungin in 24 neutropenic patients with haematological malignancies (HM) and candidaemia. These patients had received chemotherapy for HM and were neutropenic (PNN < 0.5 × 109/L) for a median of 12 days (2–41) before candidaemia. The patients received caspofungin for a median duration of 12 days (range 6–26), obtaining a favourable overall response of 58%. At 30 days, 11 patients had died (46%); candidaemia was responsible for mortality in six patients (25%). These results suggest that treatment of candidaemia with caspofungin in neutropenic HM was efficacious, as …

AdultMaleMicrobiology (medical)medicine.medical_specialtyAntifungal AgentsNeutropeniaDrug-Related Side Effects and Adverse ReactionsCandidaemia; Caspofungin; Leukaemiamedicine.medical_treatmentAntineoplastic AgentsNeutropeniaEchinocandinsLipopeptidesYoung Adultchemistry.chemical_compoundPharmacotherapyCandidaemiaCaspofunginInternal medicinemedicineHumansLeukaemiaProspective StudiescaspofunginProspective cohort studyMycosisFungemiaAgedChemotherapyHematologybusiness.industryCandidiasisGeneral MedicineMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeInfectious DiseaseschemistryHematologic NeoplasmsleukaemiaFemaleCaspofunginbusinessFungemia
researchProduct

Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter p…

2010

Adrenocortical carcinoma (ACC) is a rare neoplasm characterized by poor prognosis. First-line systemic treatments in advanced disease include mitotane, either alone or in combination with chemotherapy. Studies evaluating second-line therapy options have obtained disappointing results. This trial assessed the activity and toxicity of gemcitabine plus metronomic fluoropyrimidines in heavily pretreated advanced ACC patients. From 1998 to 2008, 28 patients with advanced ACC progressing after mitotane plus one or two systemic chemotherapy lines were enrolled. They received a combination of i.v. gemcitabine (800 mg/m2, on days 1 and 8, every 21 days) and i.v. 5-fluorouracil protracted infusion (2…

AdultMaleMucositisOncologyAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyAdrenocortical carcinomaSettore MED/06 - Oncologia MedicaEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPhases of clinical researchDeoxycytidineGastroenterologyDrug Administration ScheduleCapecitabineEndocrinologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineMucositisHumansMitotaneCapecitabineAgedChemotherapybusiness.industryLeukopeniaMiddle Agedmedicine.diseaseThrombocytopeniaGemcitabineAdrenal Cortex NeoplasmsGemcitabineRegimenTreatment OutcomeOncologyFluorouracilDisease ProgressionFemaleFluorouracilbusinessmedicine.drug
researchProduct

Heart and Skeletal Muscles: Linked by Autonomic Nervous System.

2019

Background Resting sympathetic hyperactivity and impaired parasympathetic reactivation after exercise have been described in patients with heart failure (HF). However, the association of these autonomic changes in patients with HF and sarcopenia is unknown. Objective The aim of this study was to evaluate the impact of autonomic modulation on sarcopenia in male patients with HF. Methods We enrolled 116 male patients with HF and left ventricular ejection fraction < 40%. All patients underwent a maximal cardiopulmonary exercise testing. Maximal heart rate was recorded and delta heart rate recovery (∆HRR) was assessed at 1st and 2nd minutes after exercise. Muscle sympathetic nerve activity (MSN…

AdultMaleMuscleSkeletallcsh:Diseases of the circulatory (Cardiovascular) systemSarcopeniaSympathetic Nervous Systemheart failurelihaksetBioinformaticsAutonomic Nervous SystemsarcopeniaYoung AdultOxygen ConsumptionHeart Ratehomeostasisautonominen hermostomedicinemyocardiumHomeostasisHumansBlunted Vagal Reactivation.Muscle StrengthsydäntauditMuscle SkeletalAgedsympathetic nervous systemSympathetica Nervous SystemHeart FailureHand Strengthbusiness.industryMyocardiumautonomic nervous systemHeartMiddle Agedmedicine.diseaseAutonomic nervous systemSympathetic Hyperactivitylcsh:RC666-701Heart failureSarcopeniaExercise TestOriginal Articlemuscle skeletalShort EditorialCardiology and Cardiovascular Medicinebusinesshuman activitiesHomeostasislihasvoimaArquivos brasileiros de cardiologia
researchProduct

Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma

2013

Background: Neutropenia and its complications represent one of the principal dose-limiting toxicity issues in chemotherapeutic regimens for soft tissue sarcoma. Prophylactic granulocyte colony-stimulating factor (G-CSF) reduces the risk of febrile neutropenia (FN). The correct timing of G-CSF administration should be considered in order to optimize the prophylactic treatment. Patients and Methods: Patients (≥18 years old) affected by soft tissue sarcoma and treated with epirubicin and ifosfamide, underwent prophylactic treatment with G-CSF (lenograstim at 263 μg) from day 5 to day 9. The proportion of patients experiencing FN and G4 neutropenia was considered. Results: A total of 36 patient…

AdultMaleNeutropeniaSettore MED/06 - Oncologia MedicaAntineoplastic AgentsSarcomaSoft Tissue Neoplasmslenograstrim sarcoma neutropeniaMiddle AgedLenograstim Febrile Neutropenia Soft tissue sarcomaLenograstimRecombinant ProteinsYoung AdultAdjuvants ImmunologicGranulocyte Colony-Stimulating FactorHumansFemaleIfosfamideAgedEpirubicin
researchProduct

The long-term effect of job mobility on workers' mental health: a propensity score analysis

2022

Abstract Objectives The main purpose of this longitudinal study was to elucidate the impact of external job mobility, due to a change of employer, on mental health. Methods A cohort of Belgian employees from the IDEWE occupational medicine registry was followed-up for twenty-seven years, from 1993 to 2019. The use of drugs for neuropsychological diseases was considered as an objective indicator of mental health. The covariates were related to demographic, physical, behavioural characteristics, occupational and work-related risks. Propensity scores were calculated with a Cox regression model with time-varying covariates. The PS matching was used to eliminate the systematic differences in sub…

AdultMaleOccupational MedicineDepressive disorder Epidemiology Job mobility Longitudinal study Mental health Neuropsychological treatment Adult Female Humans Longitudinal Studies Male Mental Health Propensity Score Occupational Health Occupational MedicineScience & TechnologyDepressive disorderEpidemiologyILLSettore MED/44 - Medicina Del LavoroPublic Health Environmental and Occupational HealthSettore MED/01 - Statistica MedicaMental HealthHumansNeuropsychological treatmentFemaleMental healthLongitudinal StudiesLongitudinal studyPropensity ScoreLife Sciences & BiomedicineJob mobilityOccupational HealthPublic Environmental & Occupational Health
researchProduct

Once-Daily Oral Levofloxacin Monotherapy versus Piperacillin/Tazobactam Three Times a Day: A Randomized Controlled Multicenter Trial in Patients with…

2004

A prospective, randomized, controlled multicenter trial was performed to evaluate the efficacy and safety of once-daily oral monotherapy with 500 mg levofloxacin in comparison with 4.5 g piperacillin/tazobactam 3 times a day in patients with low-risk febrile neutropenia. Low risk was defined by oral temperatureor = 38.5 degrees C on one occasion oror = 38.0 degrees C twice within 24 hours and granulocytopeniaor = 500/microL for less than 10 days. The primary end point was defined as defervescence after 72 hours followed by at least 7 afebrile days. Secondary end points were overall response, time to defervescence, survival on day 30, and toxicity. Thirty-four episodes were included. Fever o…

AdultMaleOfloxacinTazobactammedicine.medical_specialtyNeutropeniaFeverAdministration OralPenicillanic AcidAntineoplastic AgentsLevofloxacinNeutropeniaFever of Unknown OriginTazobactamDrug Administration ScheduleImmunocompromised HostLevofloxacinNeoplasmsInternal medicineMulticenter trialHumansMedicineProspective StudiesAgedAntibacterial agentPiperacillinbusiness.industryBacterial InfectionsHematologyMiddle Agedmedicine.diseaseSurgeryTreatment OutcomePiperacillin/tazobactamDrug Therapy CombinationFemaleDisease SusceptibilitySafetybusinessFebrile neutropeniaPiperacillinmedicine.drugInternational Journal of Hematology
researchProduct

Irinotecan (CPT-11) and Mitomycin-C (MMC) as Second-Line Therapy in Advanced Gastric Cancer

2005

Objective The aim of this study was to evaluate the activity and toxicity of a combination regimen of CPT-11 and mitomycin-c as second-line chemotherapy for pretreated patients with advanced, metastatic, or both, gastric adenocarcinoma. Materials and methods Patients with pretreated metastatic disease or early relapsed after adjuvant chemotherapy were enrolled. Entry criteria included histologic/cytologic diagnosis of gastric adenocarcinoma, age 18 to 75 years, performance status > or =70 (Karnofsky scale), bi-dimensionally measurable disease. Patients received CPT-11 and mitomycin-c at the dosage of 150 mg/m2 on days 1 and 15, and 8 mg/m2 on day 1, respectively, every 4 weeks. The disease …

AdultMaleOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsNeutropeniaMitomycinmedicine.medical_treatmentSalvage therapyPhases of clinical researchAdenocarcinomaNeutropeniaIrinotecanGastroenterologyDisease-Free SurvivalStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineHumansLife TablesPeritoneal NeoplasmsAgedSalvage TherapyChemotherapyLeukopeniaPerformance statusbusiness.industryLiver NeoplasmsDrug SynergismMiddle Agedmedicine.diseaseSurvival Analysistherapy gastric cancerIrinotecanRegimenTreatment OutcomeItalyOncologyLymphatic MetastasisCamptothecinFemalemedicine.symptombusinessmedicine.drugAmerican Journal of Clinical Oncology
researchProduct

Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin

2017

&lt;b&gt;&lt;i&gt;Objectives:&lt;/i&gt;&lt;/b&gt; Low body mass index (BMI) and/or low lean body mass have been shown to be risk factors for chemotherapy-related toxicities in a number of different cancers. However, no data are available regarding the role of BMI as a risk factor for developing toxicities related to the novel anticancer agent, trabectedin, in patients with soft-tissue sarcoma (STS). We evaluated the role of BMI as a risk factor for trabectedin-related toxicity in patients with STS. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; Data from 51 patients with metastatic/advanced STS treated with trabectedin after progression on ≥1 anthracycline ± ifosfamide regimen were retrospe…

AdultMaleOncologySarcopeniaCancer Researchmedicine.medical_specialtyNeutropeniaDioxolesNeutropeniaBody Mass Index03 medical and health sciences0302 clinical medicineThinnessRisk FactorsTetrahydroisoquinolinesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAnthracyclinesIfosfamide030212 general & internal medicineRisk factorAntineoplastic Agents AlkylatingTrabectedinAgedRetrospective StudiesAged 80 and overIfosfamideToxicitybusiness.industrySoft tissue sarcomanutritional and metabolic diseasesSarcomaGeneral MedicineMiddle Agedmedicine.diseaseOncology030220 oncology & carcinogenesisSoft-tissue sarcomaFemaleUnderweightmedicine.symptombusinessBody mass indexFebrile neutropeniaTrabectedinmedicine.drugOncology
researchProduct